However, also with a small number of patients we were able to find distinct changes in the immunoprofile of IFN-α treated patients and these findings should be confirmed in upcoming clinical studies evaluating the effect of IFN-α in the treatment of CML. Here, IFNA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.